Article

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation

2022-09-16

Abstract excerpt

Initial clinical trials with drugs targeting epigenetic modulators - such as bromodomain and extraterminal (BET) inhibitors - demonstrate modest results in acute myeloid leukemia (AML). The main reason for this involves an increased transcriptional plasticity within AML, which allows cells to escape the therapeutic pressure. To study mechanisms of resistance, we investigated immediate epigenetic and transcriptiona...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 75359f1e-825b-5f48-9a99-2606857caecf
DOI: 10.1101/2022.09.14.507850

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activationDOI 10.1101/2022.09.14.507850Read

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivationSemantic proximity Read

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Semantic proximity Read

Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional RemodelingSemantic proximity Read

The transcriptional regulatory circuit as a driver and therapeutic target in CML blast crisisSemantic proximity Read

Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemiaSemantic proximity Read

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical ApplicationsSemantic proximity Read

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.Semantic proximity Read

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignanciesSemantic proximity Read

BRD4-mediated repression of p53 is a target for combination therapy in AMLSemantic proximity Read

CREB-binding protein and p300: molecular integrators of hematopoietic transcriptionSemantic proximity Read

Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemiaSemantic proximity Read

p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.Semantic proximity Read